Why faster trials make participant understanding more important than ever
July 15, 2026 | Informed Consent, clinical trials, communication
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
“I was confused, didn’t understand half of what he was saying.” The clinician’s reply? “You’ll only retain 2% of what’s discussed.” Then they carried on. They didn’t go back.*
That isn’t how anyone should describe the conversation that determines whether they join a clinical trial. Regulatory reforms are removing unnecessary delays from study approval and start-up, but there’s one part of the process that can’t be compressed: ensuring people genuinely understand what they’re agreeing to.
Longer forms, same confusion
When consent comes up, the instinct is to add more: more detail, more pages, more risks spelled out. The result is documents that are comprehensive, yet largely unread.
One participant, three infusions into a cancer trial, put it plainly: “The list of potential side effects goes on for many pages. Before I could give informed consent, the risks were laid out in exacting detail. It’s hard to stay alert.”*
Patients who go looking for answers often come away with more questions. “I spent a night searching the internet and found nothing useful,” one wrote, “just terrifying statistics and medical jargon written for doctors.”*
These people weren’t asking for less information – they were asking for information they could actually understand. Because disclosure alone isn’t the same as understanding.
Consent is a conversation, not a signature
The problem isn’t always the consent form itself. Sometimes it’s what happens around it. A research coordinator, describing their own site, said the doctor “always pushes for them to sign the consent form without fully understanding the trial,” on the logic that “they’ll learn more as time goes on.” And if a participant asks to take the form home to read, or talk it over with their GP? That’s “looked at as a bad thing, since we might lose the patient.”*
That’s understandable when recruitment timelines are under pressure. But it’s also where informed consent can quietly become a process of collecting signatures rather than building understanding.
People need time to reflect, ask questions, involve family members or speak to healthcare professionals they trust. A signature doesn’t demonstrate understanding. A conversation does.
Clearer isn’t simpler
The goal of informed consent isn’t simply to disclose every possible piece of information. It’s to present information in a way people can understand, use, and act on – using plain language, structuring information logically, introducing visuals where they genuinely aid understanding, and layering information so participants can explore topics in more depth at their own pace.
And it has to work for everyone a trial hopes to reach: older participants, people with lower health literacy, caregivers deciding alongside a patient, and anyone moving between an app and a face-to-face conversation. None of that is a special accommodation. It’s just consent that works.
Why this matters more as trials speed up
Regulatory reforms such as Operation TrialBlazer, the EU Clinical Trials Regulation and the MHRA’s changes around proportionate, risk-based review are all designed to make clinical research more efficient, with faster timelines. That’s good news for patients waiting for new treatments.
Speed may shorten timelines, but it can’t shorten the responsibility to ensure genuine understanding. When people don’t fully understand what they’re joining, uncertainty doesn’t disappear after enrolment. It can resurface later as hesitation, withdrawal, missed assessments or poorer engagement throughout the study. Those challenges affect participant experience, recruitment, retention and ultimately the quality of the data a trial generates.
As trials become faster, understanding – not disclosure – becomes the measure of good consent.
Let’s talk
Clearer consent. Information people can actually use. Materials built for the full range of participants. If your study is picking up pace and you want the people in it to understand what they’re joining – and stay – let’s talk.
*We searched our index of patient and participant discussion for where people describe consenting to, or trying to understand, a clinical trial. The quotes are real, lightly edited for length, with identifying details removed. It’s a self-selected, anonymous source – illustrative, not statistically representative – but it shows, in patients’ own words, where consent is and isn’t working.
References
- US Department of Health and Human Services. Press release. Available here (accessed July 2026).
- Regulation (EU) No 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use (Clinical Trials Regulation).
- Health Research Authority. Clinical trials regulation reform. Available here (accessed July 2026).
- Health Research Authority. Informing participants and seeking consent. Available here (accessed July 2026).
- NHS England. Inclusive digital healthcare: a framework for NHS action on digital inclusion. Available here (accessed July 2026).
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Clarity in clinical trials
Discover how transparent, empathetic communication and health literacy principles can empower patients and enhance engagement in clinical trials, transforming participants into active partners in their healthcare journey.
Caring for patients’ mental health in clinical trials
We look at why ensuring continuous mental health support for patients in clinical trials is essential to enhance their overall well-being and trial engagement.
Driving equitable healthcare: The role of DE&I in clinical trials
Diversity, equity and inclusion (DE&I) is becoming a bigger topic of conversation and meaningful action within clinical trials. And for good reason, too. Find out why we embrace this and…
Empowering patients through more accessible clinical trial information
Senior Medical Writer, Scott Palmer explores the challenges and solutions in enhancing patient engagement in clinical trials, from the pivotal role of healthcare professionals, to the importance of user-friendly trial…
New report now available: Integrating ‘patient first’ into medicine development
A new report has just been published by Cuttsy+Cuttsy that collates all the current best thinking in the ‘patient first’ space, distilling it into a practical and actionable road map…
The digital prescription – enhancing the patient experience with technology
We explore how digital health innovations are revolutionising patient care by enhancing accessibility, personalisation, and engagement, promising a more connected and empowered patient experience.
Compliance — a driving force for influencing public perceptions of the pharma industry?
How does compliance play into public perceptions of pharma and why is it important for improving public opinion?
Another year, another B!
Louise Jones, Cuttsy+Cuttsy’s Sustainability Officer reflects on their latest year of carbon reporting through CDP and on achieving another B rating.
Jon Hume Joins Cuttsy+Cuttsy as New Commercial Director
Cuttsy+Cuttsy is excited to announce the appointment of Jon Hume as Commercial Director, effective 1st March 2024.
Clinical trial considerations: Why supporting HCPs matters…
When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.